Altimmune Inc (NASDAQ: ALT) closed the day trading at $7.99 down -4.88% from the previous closing price of $8.40. On the day, 3036231 shares were traded.
Ratios:
For a better understanding of ALT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.25 and its Current Ratio is at 17.25. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on January 24, 2024, initiated with a Neutral rating and assigned the stock a target price of $13.
On March 22, 2023, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $20 to $6.
On December 01, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $20.Goldman initiated its Buy rating on December 01, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’23 when Drutz David bought 300 shares for $2.88 per share. The transaction valued at 862 led to the insider holds 29,785 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1317.42 while its Price-to-Book (P/B) ratio in mrq is 2.91.
Stock Price History:
Over the past 52 weeks, ALT has reached a high of $14.84, while it has fallen to a 52-week low of $2.09.
Shares Statistics:
A total of 70.68M shares are outstanding, with a floating share count of 70.17M. Insiders hold about 1.02% of the company’s shares, while institutions hold 62.01% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from AdvisorShares Vice ETF analysts. The consensus estimate for the next quarter is $41.05, with high estimates of $279.07 and low estimates of $90.29.
EPS for the following year is $Stocks, with ETF analysts recommending between $Stocks and $ETF.
